Shares of Surmodics SRDX remained unaffected after the company reported Q2 results.
Quarterly Results
Earnings per share rose 1450.00% over the past year to $0.62, which missed the estimate of $0.63.
Revenue of $34,995,000 higher by 53.34% from the same period last year, which beat the estimate of $32,950,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Apr 28, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/3kon824t
Price Action
52-week high: $59.75
52-week low: $33.45
Price action over last quarter: Up 11.84%
Company Profile
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using our technology to provide solutions to a difficult medical device and diagnostic challenges. It has two reportable segments: Medical device unit and Vitro diagnostics unit. Surmodics derives most of its revenue from the Medical device segment.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
